首页 | 本学科首页   官方微博 | 高级检索  
检索        

经动脉化疗栓塞序贯125I植入治疗中晚期肝癌疗效观察
引用本文:欧章松,张启周,胡倩,丁林潇潇,姚和瑞.经动脉化疗栓塞序贯125I植入治疗中晚期肝癌疗效观察[J].岭南现代临床外科,2014,14(1):33-36.
作者姓名:欧章松  张启周  胡倩  丁林潇潇  姚和瑞
作者单位:1. 广东省中西医结合医院; 2. 中山大学孙逸仙纪念医院
基金项目:国家自然科学基金(编号:81372819);教育部博士点基金(编号:20120171110075);中山大学青年教师重点培育项目(编号:13ykzdl4)
摘    要:【摘要】 目的 探讨经动脉化疗栓塞术(TACE)序贯125I放射性粒子植入治疗中晚期肝癌的临床疗效。方法 回顾性研究自2011年5月至2012年5月确诊为中晚期原发性肝癌的患者89例,A组45例(单纯TACE术),B组44例(TACE术后7~10天内序贯125I放射性粒子植入),125I放射性粒子植入严格遵从计算机三维治疗计划系统(TPS)的方案进行粒子布源。对比观察两组患者术后2、4个月的CT扫描显示的肿瘤局部控制有效率及术后6、9个月的生存率,两组局部控制率及术后6、9个月生存率比较采用卡方检验。 结果 随访术后第2、4月肿瘤局部控制有效率(CR+PR)A组是24.44%(11/45),17.78%(8/45),B组为54.55%(24/44),47.73%(21/44),P<0.05,两组差异比较具有统计学意义。A组术后6、9个月存活率分别是62.22%(28/45),42.22%(19/45),B组术后6、9个月存活率分别是90.91%(40/44),72.73%(32/44),两组同期P值均小于0.05,两组差异具有统计学意义。结论 经肝动脉化疗栓塞序贯125I放射性粒子植入治疗中晚期原发性肝癌临床疗效确切,提高生存率。

关 键 词:肝细胞癌  经动脉化疗栓塞术  125I放射性粒子  

Curative effect of transcatheter arterial combined with mI implantation in the treatment of Middle-advanced hepatic carcinoma
Ou Zhangsong,Zhang Qizhoua,Hu Qianb,Ding-Lin Xiaoxiaob,Yao Herui.Curative effect of transcatheter arterial combined with mI implantation in the treatment of Middle-advanced hepatic carcinoma[J].Lingnan Modern Clinics in Surgery,2014,14(1):33-36.
Authors:Ou Zhangsong  Zhang Qizhoua  Hu Qianb  Ding-Lin Xiaoxiaob  Yao Herui
Institution:1.Guangdong Province Hospital of combination of traditional Chinese and Western Medicine 2.Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Abstract:Objective To discuss the therapeutic effect of transcatheter hepatic arterial chemoemb- olization (TACE) combined with radioactive particles implantation for the treatment of middle advanced hepatic carcinoma. Methods Eighty-nine cases of hepatic carcinoma were collected from May 2011 to May 2012 and retrospectively analyzed. Of 89 cases, 45 patients were underwent TACE alone (group A), 44 were treated with TACE combined with radioactive particles implantation (group B) under the computer-assisted three-dimensional treatment planning system (TPS). Efficacy evaluation was performed in two months, four months after operation by CT scan. The survival status was recorded in the fourth and ninth months after treatment. Efficacy evaluation and survival status were compared between two groups by chi-square test (P〈0.05). Results The OR (CR+PR) were 24.44% (11/45), 17.78% (8/45) in group A, and 54.55% (24/44), 47.73% (21/44) in group B respectively at two months and four months after operation. There were significant differences between two groups (P〈0.05). The survival rate at six, nine months in group A (62.22%, 42.22%) were significantly lower than those in group B (90.91% ,72.73% ),P〈0.05, Conclusion TACE combined with 125I radioactive particles implantation is an effective method for the treatment of middle- advanced hepatic carcinoma, which would also improved survival rate.
Keywords:Hepatocellular carcinoma  TACE 125I radioactive particles
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《岭南现代临床外科》浏览原始摘要信息
点击此处可从《岭南现代临床外科》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号